Lawes, C. M., Vander Hoorn, S., Rodgers, A.: Global burden of blood-pressure-related disease, 2001. Lancet, 2008, 371(9623), 1513–1518.

Globocan 2008. Cancer incidence and mortality worldwide. WHO, International Agency for Research on Cancer. http://www.iarc.fr/en/media-centre/iarcnews/2010/globocan2008.php

Globocan 2012. Estimated cancer incidence, mortality and prevalence worldwide in 2012. WHO, International Agency for Research on Cancer. http://globocan.iarc.fr/Default.aspx

Kiss, I., Telekes, A.: Cancer and hypertension. In: Farsang, Cs. (ed.): Textbook of hypertension. [Daganatos betegségek és hypertonia. In: Farsang, Cs. (szerk.): A hypertonia kézikönyve.] Medintel Kiadó, Budapest, 2002. [Hungarian]

Sipahi, I., Debanne, S. M., Rowland, D. Y., et al.: Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials. Lancet Oncol., 2010, 11(7), 627–636.

Farsang, Cs.: On the safety of angiotensinreceptor blockers – A new attack on this drug class. [Az angiotenzinreceptor-blokkolók biztonságosságáról. Újabb támadás e gyógyszercsoport ellen.] Lege Artis Med., 2010, 20(8), 473–477. [Hungarian]

Dézsi, Cs. A.: In the mirror of clinical studies: Angiotensin II receptor blockers and risk of cancer. [A klinikai vizsgálatok tükrében: Az angiotensin-II-receptor-blokkolók és a rák kockázata.] Háziorvosi Továbbképző Szemle, 2013, 18(8), 521–526. [Hungarian]

Volpe, M., Azizi, M., Danser, A. H., et al.: Twisting arms to angiotensin receptor blockers/antagonists: the turn of cancer. Eur. Heart J., 2011, 32(1), 19–22.

George, A. J., Thomas, W. G., Hannan, R. D.: The renin-angiotensin system and cancer: old dog, new tricks. Nat. Rev. Cancer, 2010, 10(11), 745–759.

Deshayes, F., Nahmias, C.: Angiotensin receptors: a new role in cancer? Trends Endocrinol. Metab., 2005, 16(7), 293–299.

Chung, O., Csikós, T., Unger, T.: Angiotensin II receptor pharmacology and AT1-receptor blockers. J. Hum. Hypertens., 1999, 13(Suppl. 1), S11–S20.

Chung, O., Kühl, H., Stoll, M., et al.: Physiological and pharmacological implications of AT1 versus AT2 receptors. Kidney Int. 1998, 67(Suppl.), S95–S99.

Egami, K., Murohara, T., Shimada, T., et al.: Role of host angiotensin II type 1 receptor in tumor angiogenesis and growth. J. Clin. Invest., 2003, 112(1), 67–75.

Suzuki, Y., Ruiz-Ortega, M., Lorenzo, O., et al.: Inflammation and angiotensin II. Int. J. Biochem. Cell Biol., 2003, 35(6), 881–900.

Sano, H., Hosokawa, K., Kidoya, H., et al.: Negative regulation of VEGF-induced vascular leakage by blockade of angiotenzin II type 1 receptor. Arterioscler. Thromb. Vasc. Biol., 2006, 26(12), 2673–2680.

Ager, E. I., Neo, J., Cristophi, C.: The renin-angiotensin system and malignancy. Carcinogenesis, 2008, 29(9), 1675–1684.

Silvestre, J. S., Tamarat, R., Senbonmatsu, T., et al.: Antiangiogenic effect of angiotensin II type 2 receptor in ischemia-induced angiogenesis in mice hindlimb. Circ. Res., 2002, 90(10), 1072–1079.

Link, W. T., De Felice, A.: An FDA overview of rodent carcinogenicity studies of angiotensin II AT-1 receptor blockers: Pulmonary adenomas and carcinomas. Regul. Toxicol. Pharmacol., 2014, 70(2), 555–563.

Gong, Q., Davis, M., Chipitsyna, G., et al.: Blocking angiotensin II type 1 receptor triggers apoptotic cell death in human pancreatic cancer cells. Pancreas, 2010, 39(5), 581–594.

Uemura, H., Ishiguro, H., Nagashima, Y., et al.: Antiproliferative activity of angiotensin II receptor blocker through cross-talk between stromal and epithelial prostate cancer cells. Mol. Cancer Ther., 2005, 4(11), 1699–1709.

Suganuma, T., Ino, K., Shibata, K., et al.: Functional expression of the angiotensin II type 1 receptor in human ovarian carcinoma cells and its blockade therapy resulting in suppression of tumor invasion, angiogenesis and peritoneal dissemination. Clin. Cancer Res., 2005, 11(7), 2686–2694.

Schupp, N., Schmid, U., Rutkowski, P., et al.: Angiotenzin II-induced genomic damage in renal cells can be prevented by angiotensin II type 1 receptor blockage or radical scavenging. Am. J. Physiol. Renal Physiol., 2007, 292(5), F1427–F1434.

Kinoshita, J., Fushida, S., Harada, S., et al.: Local angiotensin II-generation in human gastric cancer: correlation with tumor progression through the activation of ERK1/2, NF-kappaB and surviving. Int. J. Oncol., 2009, 34(6), 1573–1582.

Herr, D., Rodewald, M., Fraser, H. M., et al.: Potential role of Renin-Angiotensin-system for tumor angiogenesis in receptor negative breast cancer. Gynecol. Oncol., 2008, 109(3), 418–425.

Arafat, H. A., Gong, Q., Chipitsyna, G., et al.: Antihypertensives as novel antineoplastics: angiotensin-I-converting enzyme inhibitors and angiotensin II type 1 receptor blockers in pancreatic ductal adenocarcinoma. J. Am. Coll. Surg., 2007, 204(5), 996–1005.

Noguchi, R., Yoshiji, H., Ikenaka, Y., et al.: Synergistic inhibitory effect of gemcitabine and angiotensin type-1 receptor blocker, losartan, on murine pancreatic tumor growth via anti-angiogenic activities. Oncol. Rep., 2009, 22(2), 355–360.

Redondo-Müller, M. A., Stevanovic-Walker, M., Barker, S., et al.: Anti-cancer actions of recombinant antibody (R6313/G2) against the angiotensin II AT1 receptor. Endocr. Relat. Cancer, 2008, 15(1), 277–288.

Uemura, H., Ishiguro, H., Kubota, Y.: Angiotensin II receptor blocker: possibility of antitumor agent for prostate cancer. Mini Rev. Med. Chem., 2006, 6(7), 835–844.

Ino, K., Shibata, K., Kajiyama, H., et al.: Manipulating the angiotensin system – new approaches to the treatment of solid tumors. Expert Opin. Biol. Ther., 2006, 6(3), 243–255.

Da, Y. J., Yuan, W. D., Zhu, L. F., et al.: Synthesis, anti-hypertensive effect of a novel angiotensin II AT1 receptor antagonist and its anti-tumor activity in prostate cancer. Arzneimittelforschung, 2012, 62(12), 637–643.

Takahashi, S., Uemura, H., Seeni, A., et al.: Therapeutic targeting of angiotensin II receptor type 1 to regulate androgen receptor in prostate cancer. Prostate, 2012, 72(14), 1559–1572.

Funao, K., Matsuyama, M., Kawahito, Y., et al.: Telmisartan is a potent target for prevention and treatment in human prostate cancer. Oncol. Rep., 2008, 20(2), 295–300.

Koyama, N., Nishida, Y., Ishii, T., et al.: Telmisartan induces growth inhibition, DNA double-strand breaks and apoptosis in human endometrial cancer cells. PLoS ONE, 2014, 9(3), e93050.

Li, J., Chen, L., Yu, P., et al.: Telmisartan exerts anti-tumor effects by activating peroxisome proliferator-activated receptor-γ in human lung adenocarcinoma A549 cells. Molecules, 2014, 19(3), 2862–2876.

Verhoest, G., Dolley-Hitze, T., Jouan, F., et al.: Sunitinib combined with angiotensin-2 type-1 receptor antagonists induces more necrosis: a murine xenograft model of renal cell carcinoma. BioMed Res. Int., 2014, 2014, 901371.

Pfeffer, M. A., Swedberg, K., Granger, C. B., et al.: Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet, 2003, 362(9386), 759–766.

Bangalore, S., Kumar, S., Kjeldsen, S. E., et al.: Antihypertensive drugs and risk of cancer: network meta analyses and trial sequential analyses of 324,168 participants from randomized trials. Lancet Oncol., 2011, 12(1), 65–82.

ARB Trialists Collaboration: Effects of telmisartan, irbesartan, valsartan, candesartan, and losartan on cancers in 15 trials enrolling 138,769 individuals. J. Hypertens., 2011, 29(4), 623–635.

Pasternak, B., Svanström, H., Callréus, T., et al.: Use of angiotensin receptor blockers and the risk of cancer. Circulation, 2011, 123(16), 1729–1736.

Opelz, G., Döhler, B.: Treatment of kidney transplant recipients with ACEi/ARB and risk of respiratory tract cancer: a collaborative transplant study report. Am. J. Transplant., 2011, 11(11), 2483–2489.

Sugiura, R., Ogawa, H., Oka, T., et al.: Candesartan-based therapy and risk of cancer in patients with systemic hypertension (Heart Institute of Japan Candesartan Randomized Trial for Evaluation in Coronary Artery Disease [HIJ-CREATE] substudy). Am. J. Cardiol., 2012, 109(4), 576–580.

Huang, C. C., Chan, W. L., Chen, Y. C., et al.: Angiotensin II receptor blockers and risk of cancer in patients with systemic hypertension. Am. J. Cardiol., 2011, 107(7), 1028–1033.

Chang, C. H., Lin, J. W., Wu, L. C., et al.: Angiotensin receptor blockade and risk of cancer in type 2 diabetes mellitus: a nationwide case-control study. J. Clin. Oncol., 2011, 29(22), 3001–3007.

Chiang, Y. Y., Chen, K. B., Tsai, T. H., et al.: Lowered cancer risk with ACE inhibitors/ARBs: a population-based cohort study. J. Clin. Hypertens (Greenwich), 2014, 16(1), 27–33.

Azoulay, L., Assimes, T. L., Yin, H., et al.: Long-term use of angiotensin receptor blockers and the risk of cancer. PLoS ONE 2012, 7(12), e50893.

Chin, H. J., Oh, S. W., Goo, H. S., et al., Members of the PREMIER Group: Effect of RAAS inhibition on the incidence of cancer and cancer mortality in patients with glomerulonephritis. J. Korean Med. Sci., 2011, 26(1), 59–66.

Yuge, K., Miyajima, A., Tanaka, N., et al.: Prognostic value of renin-angiotensin system blockade in non-muscle-invasive bladder cancer. Ann. Surg. Oncol., 2012, 19(12), 3987–3993.

Rao, G. A., Mann, J. R., Shoaibi, A., et al.: Angiotensin receptor blockers: are they related to lung cancer? J. Hypertens., 2013, 31(8), 1669–1675.

Rao, G. A., Mann, J. R., Bottai, M., et al.: Angiotensin receptor blockers and risk of prostate cancer among United States veterans. J. Clin. Pharmacol., 2013, 53(7), 773–778.

Holmes, S., Griffith, E. J., Musto, G., et al.: Antihypertensive medications and survival in patients with cancer: a population-based retrospective cohort study. Cancer Epidemiol., 2013, 37(6), 881–885.

Sørensen, G. V., Ganz, P. A., Cole, S. W., et al.: Use of β-blockers, angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and risk of breast cancer recurrence: a Danish nationwide prospective cohort study. J. Clin. Oncol., 2013, 31(18), 2265–2272.

Makar, G. A., Holmes, J. H., Yang, Y. X.: Angiotensin-converting enzyme inhibitor therapy and colorectal cancer risk. J. Natl. Cancer Inst., 2014, 106(2), djt374.

Engineer, D. R., Burney, B. O., Hayes, T. G., et al.: Exposure to ACEI/ARB and β-blockers is associated with improved survival and decreased tumor progression and hospitalizations in patients with advanced colon cancer. Transl. Oncol., 2013, 6(5), 539–545.

Cardwell, C. R., Mc Menamin, Ú. C., Hicks, B. M., et al.: Drugs affecting the renin-angiotensin system and survival from cancer: a population based study of breast, colorectal and prostate cancer patient cohorts. BMC Med., 2014, 12, 28. http://www.biomedcentral.com/1741-7015/12/28

Mc Menamin, Ú. C., Murray, L. J., Cantwell, M. M., et al.: Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in cancer progression and survival: a systematic review. Cancer Causes Control, 2012, 23(2), 221–230.

Nakai, Y., Isayama, H., Ijichi, H., et al.: Inhibition of renin-angiotensin system affects prognosis of advanced pancreatic cancer receiving gemcitabine. Br. J. Cancer, 2010, 103(11), 1644–1648.

Kim, S. T., Park, K. H., Oh, S. C., et al.: How does inhibition of the renin-angiotensin system affect the prognosis of advanced gastric cancer patients receiving platinum-based chemotherapy? Oncology, 2012, 83(6), 354–360.

Chen, Y. H., Huang, C. H., Lu, H. I., et al.: Prognostic impact of renin-angiotensin system blockade in esophageal squamous cell carcinoma. J. Renin Angiotensin Aldosterone Syst., 2014 Jun 24. pii: 1470320314535275. [Epub ahead of print]

Chauhan, V. P., Martin, J. D., Liu, H., et al.: Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels. Nat. Commun., 2013, 4, 2516. www.nature.com/naturecommunications

Meradith, P.: Comparative ARB pharmacology. Br. J. Cardiol., 2010, 17(Suppl. 2), S3–S5.

Egan, G., Lee, J., Minhas, R., et al.: Does outcome reporting bias “cause” cancer? Risks associated with hidden data on angiotensin receptor blockers. Can. J. Hosp. Pharm., 2012, 65(5), 387–393.

FDA Drug Safety Communication: No increase in risk of cancer with certain blood pressure drugs – angiotensin receptor blockers (ARBs). www.fda.gov/Drugs/DrugsSafety/ucm257516.htm